CN1221278C - 一种治疗中风和偏头痛的脑安制剂的制备方法 - Google Patents
一种治疗中风和偏头痛的脑安制剂的制备方法 Download PDFInfo
- Publication number
- CN1221278C CN1221278C CN200310103217.7A CN200310103217A CN1221278C CN 1221278 C CN1221278 C CN 1221278C CN 200310103217 A CN200310103217 A CN 200310103217A CN 1221278 C CN1221278 C CN 1221278C
- Authority
- CN
- China
- Prior art keywords
- preparation
- percolate
- naoan
- brain
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 24
- 208000006011 Stroke Diseases 0.000 title claims abstract description 16
- 206010008190 Cerebrovascular accident Diseases 0.000 title claims abstract description 15
- 239000009999 naoan Substances 0.000 title abstract description 16
- 208000019695 Migraine disease Diseases 0.000 title abstract description 3
- 206010027599 migraine Diseases 0.000 title abstract description 3
- 239000000843 powder Substances 0.000 claims abstract description 22
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 16
- 238000005325 percolation Methods 0.000 claims abstract description 15
- 241000208340 Araliaceae Species 0.000 claims abstract description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 14
- 238000001035 drying Methods 0.000 claims abstract description 14
- 235000008434 ginseng Nutrition 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940116229 borneol Drugs 0.000 claims abstract description 5
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 5
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 5
- 210000004556 brain Anatomy 0.000 claims description 46
- 239000003814 drug Substances 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 239000006187 pill Substances 0.000 claims description 27
- 241000628997 Flos Species 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 11
- 239000012567 medical material Substances 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 17
- 230000003727 cerebral blood flow Effects 0.000 abstract description 11
- 238000001727 in vivo Methods 0.000 abstract description 8
- 230000000202 analgesic effect Effects 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 230000000857 drug effect Effects 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 244000020518 Carthamus tinctorius Species 0.000 abstract 3
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 3
- 244000061520 Angelica archangelica Species 0.000 abstract 2
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 2
- 241000112528 Ligusticum striatum Species 0.000 abstract 2
- 238000009835 boiling Methods 0.000 abstract 1
- 238000004134 energy conservation Methods 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 238000010992 reflux Methods 0.000 abstract 1
- 238000002791 soaking Methods 0.000 abstract 1
- 238000001291 vacuum drying Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 14
- 230000002792 vascular Effects 0.000 description 13
- 230000002490 cerebral effect Effects 0.000 description 12
- 231100000682 maximum tolerated dose Toxicity 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 206010033799 Paralysis Diseases 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000000702 anti-platelet effect Effects 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004004 carotid artery internal Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000269 carotid artery external Anatomy 0.000 description 2
- 238000004939 coking Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000005622 photoelectricity Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical class NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008542 thermal sensitivity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
性别 | N | 给药前(S) | 给药后第7天(S) |
雄性 | 10 | 19.2±1.1 | 26.7±1.7 |
雌性 | 10 | 19.1±0.8 | 25.9±1.4 |
组别剂量 | 盐水组 | 脑安胶囊组100.3mg/kg | 脑安滴丸组80.2mg/kg | 脑安滴丸组160.4mg/kg |
药前值15min30min45min60min90min120min | 0.0741±0.00840.0735±0.00840.0752±0.00700.0711±0.01000.0722±0.00710.0738±0.00540.0702±0.0086 | 0.0747±0.00620.0792±0.00480.0763±0.00480.0721±0.00770.0666±0.01020.0580±0.0091*0.0638±0.0067 | 0.0786±0.01350.0822±0.01690.0797±0.02220.0765±0.01130.0680±0.00600.0561±0.0094**0.0637±0.0061 | 0.0712±0.00710.0732±0.01100.0686±0.00770.0639±0.00850.0600±0.00650.0527±0.0078**0.0579±0.0082 |
组别剂量 | 盐水组 | 脑安胶囊组100.3mg/kg | 脑安滴丸组80.2mg/kg | 脑安滴丸组160.4mg/kg |
药前值15min30min45min60min90min120min | 234.23±62.79241.07±55.23231.63±47.89242.36±67.74243.44±52.57232.05±46.42242.71±51.71 | 238.28±31.97237.43±24.72238.04±22.97250.23±44.60270.35±49.17305.77±49.68*271.66±36.34 | 230.53±39.68222.25±44.79227.38±44.91235.49±47.68264.29±30.04315.68±54.15*276.25±35.43 | 234.16±31.27232.68±39.41238.90±20.48257.86±24.11272.59±29.15306.62±32.81*285.37±25.55 |
组别 | 剂量(mg/kg) | 血栓形成时间(S) |
生理盐水脑安胶囊脑安滴丸 | 333.3266.7533.3 | 665.8±57.5775.4±98.6*794.5±103.2*891.3±125.8** |
组别 剂量(mg/kg) | 血栓长度(mm) | 血栓湿重(g) | 血栓干重(g) |
生理盐水脑安胶囊333.3脑安滴丸266.7533.3 | 6.32±1.145.01±0.97*4.99±0.67*4.63±1.11** | 0.287±0.0800.254±0.053*0.237±0.033*0.222±0.075* | 0.143±0.0540.104±0.028*0.104±0.032*0.092±0.031* |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200310103217.7A CN1221278C (zh) | 2003-10-30 | 2003-10-30 | 一种治疗中风和偏头痛的脑安制剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200310103217.7A CN1221278C (zh) | 2003-10-30 | 2003-10-30 | 一种治疗中风和偏头痛的脑安制剂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1539461A CN1539461A (zh) | 2004-10-27 |
CN1221278C true CN1221278C (zh) | 2005-10-05 |
Family
ID=34333245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200310103217.7A Expired - Lifetime CN1221278C (zh) | 2003-10-30 | 2003-10-30 | 一种治疗中风和偏头痛的脑安制剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1221278C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103349692B (zh) * | 2013-05-13 | 2015-04-01 | 中国人民解放军第三七一医院 | 一种治疗偏头痛、三叉神经疼痛的中药制剂 |
CN114886933A (zh) * | 2022-06-23 | 2022-08-12 | 安徽雷允上药业有限公司 | 一种脑安滴丸提取工艺 |
-
2003
- 2003-10-30 CN CN200310103217.7A patent/CN1221278C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1539461A (zh) | 2004-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20110132407A (ko) | 인플루엔자의 예방 및 치료를 위한 식물 추출물 조성물 | |
CN102319294B (zh) | 双香草制剂及其制备方法 | |
CN103417846B (zh) | 一种降糖的中药组合物及其制备方法 | |
CN101780227B (zh) | 一种治疗中风急性期的中药组合物及其制备方法 | |
CN1247231C (zh) | 一种产后补血保健药物及其制备方法和应用 | |
CN102145057A (zh) | 一种抗痉挛的中药组合物及其制备方法 | |
CN102258742A (zh) | 一种治疗抑郁症的中药组合物及其制备方法 | |
CN1221278C (zh) | 一种治疗中风和偏头痛的脑安制剂的制备方法 | |
CN1931276B (zh) | 一种治疗头痛的中药组合物及其制备方法 | |
CN101732585A (zh) | 一种治疗偏头痛的药物组合物、制备方法及用途 | |
CN104147544A (zh) | 一种治疗慢性肛窦炎的中药组合物 | |
CN104435669B (zh) | 治疗感染性休克并发多脏器功能不全综合征的中药组合物 | |
CN103520684B (zh) | 一种降血糖的中药复合物 | |
CN1290528C (zh) | 一种治疗牙痛的药物 | |
CN102552677B (zh) | 黄地安消胶囊及其制备方法 | |
CN105796620A (zh) | 三七及三七提取物在制备治疗银屑病药物方面的新用途 | |
CN101884664B (zh) | 一种防治类风湿性关节炎的药物组合物及其制备方法 | |
CN105998752B (zh) | 一种防治血管性痴呆的中药组合物 | |
CN104587389A (zh) | 一种治疗颈肩腰腿痛的中药组合物 | |
CN116726083B (zh) | 一种治疗慢性前列腺炎的中药组合物 | |
CN111494446B (zh) | 治疗胆绞痛的中药组合物及其应用 | |
CN100551404C (zh) | 利水消肿药物组合物的制备与检测方法和用途 | |
CN102357184B (zh) | 一种治疗咳嗽的中药制剂及其制备方法 | |
CN105687499A (zh) | 一种含有倍他洛尔的治疗高血压的药物组合物及其制备方法 | |
CN105395791A (zh) | 一种无痛人流手术麻醉用的中药药物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PP01 | Preservation of patent right |
Effective date of registration: 20070618 Pledge (preservation): Preservation |
|
PD01 | Discharge of preservation of patent |
Date of cancellation: 20080618 Pledge (preservation): Preservation registration |
|
ASS | Succession or assignment of patent right |
Owner name: LIAOYUAN YULONGYA PHARMACEUTICAL CO.LTD. ADDRESS Free format text: FORMER OWNER: LIAOYUAN YADONG MEDICINE CO., LTD., JILIN PROVINCE ADDRESS Effective date: 20081121 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20081121 Address after: Jilin city of Liaoyuan province Yiyang Friendship Road No. 5 Patentee after: LIAOYUAN YULONGYADONG PHARMACEUTICAL Co.,Ltd. Address before: No. 33 Youyi Road, Jilin, Liaoyuan Patentee before: Jilin Liaoyuan Yadong Pharmaceutical Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: LIAOYUAN YULONGYA PHARMACEUTICAL CO.LTD. Free format text: FORMER OWNER: LIAOYUAN YADONG MEDICINE CO., LTD., JILIN PROVINCE Effective date: 20081121 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20190805 Address after: 236800 Baihe Road 1177, Bozhou Economic Development Zone, Anhui Province Patentee after: Anhui Yulong Yadong Pharmaceutical Co.,Ltd. Address before: 136200 No. 5 Youyiyang Road, Liaoyuan City, Jilin Province Patentee before: LIAOYUAN YULONGYADONG PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: 236000 No. 1177 Baihe Road, high tech Zone, Bozhou City, Anhui Province Patentee after: Anhui leiyunshang Pharmaceutical Co.,Ltd. Address before: 236800 no.1177 Baihe Road, Bozhou Economic Development Zone, Anhui Province Patentee before: Anhui Yulong Yadong Pharmaceutical Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CX01 | Expiry of patent term |
Granted publication date: 20051005 |
|
CX01 | Expiry of patent term |